How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,867 results for

Coronary Artery Disease Prevention in Diabetes

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease

or peripheral artery disease have serious concerns about the risk of having events such as heart attack and stroke. They noted that coronary or peripheral artery disease is a challenging condition requiring significant lifestyle adjustments, including diet and exercise, which can affect the whole family. It is important that people understand why they are being offered a dual therapy and how the drugs work, Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery (...) Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease T echnology appraisal guidance Published: 17 October 2019 www.nice.org.uk/guidance/ta607 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

2. An omega-3 fatty acid plasma index ≥4% prevents progression of coronary artery plaque in patients with coronary artery disease on statin treatment. (Abstract)

An omega-3 fatty acid plasma index ≥4% prevents progression of coronary artery plaque in patients with coronary artery disease on statin treatment. Higher blood levels of the omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been associated with fewer cardiovascular events and lower mortality in prospective studies. Our aim was to determine a target level of EPA and DHA to prevent progression of coronary artery plaque.218 subjects with stable coronary artery (...) assigned to EPA and DHA had increased plasma EPA and DHA levels variably from 1.85% to 13.02%. Plasma omega-3 fatty acid index ≥4% prevented progression of fibrous, noncalcified, calcified and total plaque in nondiabetic subjects whereas those in the lowest quartile (<3.43%) had significant progression of fibrous, calcified and total plaque. No difference was observed in diabetic subjects.EPA and DHA added to statins prevented coronary plaque progression in nondiabetic subjects with mean LDL-C <80 mg

2019 Atherosclerosis Controlled trial quality: uncertain

3. An Update on Radial Artery Access and Best Practices for Transradial Coronary Angiography and Intervention in Acute Coronary Syndrome

needed to treat with TRA to prevent 1 major bleeding event was 47 (95% CI, 35–79). Figure 1. Rates of major bleeding at 30 days or longest follow-up after transradial or transfemoral percutaneous coronary intervention in trials (A) that enrolled patients with either stable ischemic heart disease (SIHD) or acute coronary syndromes (ACS) or (B) that enrolled only patients with ACS. ACCESS indicates Acute Candesartan Cilexetil Therapy in Stroke Survivors; BRAFE, Brafe Stent Study Group; FARMI, Five (...) percutaneous coronary intervention in trials that enrolled patients with either stable ischemic heart disease or acute coronary syndromes. ACCESS indicates Acute Candesartan Cilexetil Therapy in Stroke Survivors; BRAFE, Brafe Stent Study Group; FARMI, Five French Arterial Access With Reopro in Myocardial Infarction trial; MATRIX, Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX; OR, odds ratio; OUTCLAS, Outpatient Coronary Low Profile Angioplasty Study

2018 American Heart Association

4. Dual antiplatelet therapy versus aspirin monotherapy in diabetics with stable ischemic heart disease undergoing coronary artery bypass grafting. Full Text available with Trip Pro

Dual antiplatelet therapy versus aspirin monotherapy in diabetics with stable ischemic heart disease undergoing coronary artery bypass grafting. Dual antiplatelet therapy (DAPT) in patients presenting with acute coronary syndrome (ACS) undergoing CABG is recommended to prevent recurrent ischemic events. The benefit of DAPT post-CABG in patients with stable ischemic heart disease (SIHD) is unknown. The aim of this study was to evaluate the utilization rate of DAPT and associated outcomes (...) in patients with SIHD undergoing CABG via a secondary analysis of Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial data.In a post-hoc, nonrandomized analysis from the BARI 2D trial, we compared patients receiving DAPT and aspirin monotherapy within 90 days post-randomization. The primary outcome was the risk adjusted 5-year composite of all-cause mortality, nonfatal myocardial infarction (MI), or stroke. We analyzed patients assigned to prompt CABG treatment arm including both

2018 Annals of cardiothoracic surgery Controlled trial quality: predicted high

5. Erratum: Correction of Figure. The Implication of Coronary Artery Calcium Testing for Cardiovascular Disease Prevention and Diabetes Full Text available with Trip Pro

Erratum: Correction of Figure. The Implication of Coronary Artery Calcium Testing for Cardiovascular Disease Prevention and Diabetes This corrects the article on p. 47 in vol. 32, PMID: 28345316.Copyright © 2017 Korean Endocrine Society.

2017 Endocrinology and Metabolism

6. The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study Full Text available with Trip Pro

The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study Patients with type 2 diabetes present with an accelerated atherosclerotic process. Animal evidence indicates that dipeptidyl peptidase-4 inhibitors (gliptins) have anti-inflammatory and anti-atherosclerotic effects, yet clinical data are scarcely available.A prospective, randomized, open-label study (...) was performed in 60 patients with coronary artery disease (CAD) and type 2 diabetes, who participated in a cardiac rehabilitation program. After a washout period of 3 weeks, patients were randomized in a 2:1 ratio to receive combined vildagliptin/metformin therapy (intervention group: n = 40) vs. metformin alone (control group: n = 20) for a total of 12 weeks. Blinded assessment of interleukin-1ß (IL-1ß, the primary endpoint), hemoglobin A1c (HbA1c), and high sensitivity C reactive protein (hsCRP), were

2017 Cardiovascular diabetology Controlled trial quality: uncertain

7. The Implication of Coronary Artery Calcium Testing for Cardiovascular Disease Prevention and Diabetes Full Text available with Trip Pro

The Implication of Coronary Artery Calcium Testing for Cardiovascular Disease Prevention and Diabetes Over the last two decades coronary artery calcium (CAC) scanning has emerged as a quick, safe, and inexpensive method to detect the presence of coronary atherosclerosis. Data from multiple studies has shown that compared to individuals who do not have any coronary calcifications, those with severe calcifications (i.e., CAC score >300) have a 10-fold increase in their risk of coronary heart (...) for coronary heart disease, or when intensification of treatment is being considered but has an uncertain role. This review will highlight some of the recent data on CAC testing, while focusing on the implications of those findings on patient management. The evolving role of CAC in patients with diabetes will also be highlighted.Copyright © 2017 Korean Endocrine Society.

2017 Endocrinology and Metabolism

8. Blood pressure distribution and control in coronary patients from 24 European countries in the European Society of Cardiology EURoObservational Research Programme European survey of cardiovascular disease prevention and diabetes. EUROASPIRE IV Registry. (Abstract)

Blood pressure distribution and control in coronary patients from 24 European countries in the European Society of Cardiology EURoObservational Research Programme European survey of cardiovascular disease prevention and diabetes. EUROASPIRE IV Registry. Hypertension is the most prevalent major independent risk factor for developing coronary heart disease (CHD). The present analysis aimed to assess blood pressure (BP) distribution and factors associated with insufficient BP control in coronary (...) patients.A total of 7998 patients (response rate, 48.7%) attended the follow-up visit. Complete data were available in 7653 participants (mean age 62.5 ± 9.6 years). The BP goal was achieved in 57.6%. Patients failing to achieve the BP goal were older, had higher BMI, had more often a history of coronary artery bypass grafting (CABG) and reported diabetes more frequently. Logistic regression confirmed the following independent significant predictors of not achieving the BP goal: a history of diabetes

2019 Journal of Hypertension

9. Optimal Exercise Programs for Patients With Peripheral Artery Disease: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

Optimal Exercise Programs for Patients With Peripheral Artery Disease: A Scientific Statement From the American Heart Association Optimal Exercise Programs for Patients With Peripheral Artery Disease: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 (...) walking, can be beneficial to improve walking ability and functional status. PAD indicates peripheral artery disease; and QOL, quality of life. Adapted from Gerhard-Herman et al. Copyright © 2016, American Heart Association, Inc. In 2017, the Centers for Medicare & Medicaid Services evaluated the large body of evidence demonstrating the efficacy of exercise to improve symptoms, functioning, and quality of life in patients with PAD. This has resulted in a national coverage determination of supervised

2019 American Gastroenterological Association Institute

10. Implementation of Supervised Exercise Therapy for Patients With Symptomatic Peripheral Artery Disease: A Science Advisory From the American Heart Association Full Text available with Trip Pro

exercise is not feasible, the alternative exercise methods described below should be considered. outlines conditions that may occur during SET that should interrupt SET and prompt a referral back to the patient’s clinician or another responsible healthcare provider. Table 3. An Exercise Test Is Indicated for the Following Underlying Cardiac Conditions Myocardial infarction in the past 12 mo History of stable angina pectoris Heart failure Prior coronary artery bypass surgery Prior coronary angioplasty (...) be treated before the patient begins a SET program. The patient should be capable of participation. It is the opinion of this writing group that patients with current or prior symptomatic cardiac disease ( ) who are limited by claudication should undergo an exercise test to assess for evidence of exercise-induced coronary ischemia to identify patients who may require additional treatment for cardiac disease before proceeding with SET. Limiting gait disorders may be gauged by history, observation

2019 American Heart Association

11. Drug Eluting Stents for Patients with Diabetes and Coronary Artery Disease: A Review of the Clinical Evidence and Guidelines

):281-6. 4. Aronson D, Edelman ER. Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord [Internet]. 2010 Mar [cited 2012 Sep 18];11(1):75-86. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076727/pdf/nihms252565.pdf 5. Majid A. Prevention and management of coronary artery disease in patients with diabetes mellitus. Acta Med Indones [Internet]. 2009 Jan [cited 2012 Sep 18];41(1):41-4 (...) , provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Drug Eluting Stents for Patients with Diabetes and Coronary Artery Disease: A Review of the Clinical Evidence and Guidelines DATE: 18 October 2012 CONTEXT AND POLICY ISSUES Diabetes is strongly

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. Altered asparagine and glutamate homeostasis precede coronary artery disease and type-2 diabetes. Full Text available with Trip Pro

Altered asparagine and glutamate homeostasis precede coronary artery disease and type-2 diabetes. Type 2 diabetes mellitus (T2DM) is accompanied by an increased risk for coronary artery disease (CAD), but the overlapping metabolic disturbances preceding both diseases are insufficiently described.We hypothesized that alterations in metabolism occur years before clinical manifestation of T2DM and CAD and that these alterations are reflected in the plasma metabolome. We thus aimed to identify (...) plasma metabolites that predict future T2DM and CAD.Through use of targeted liquid chromatography-mass spectrometry, 35 plasma metabolites (amino acid metabolites and acylcarnitines) were quantified in 1049 individuals without CAD and diabetes, drawn from a population sample of 5386 in the Malmö Preventive Project (mean age, 69.5 years; 31% women). The sample included 204 individuals who developed T2DM, 384 who developed CAD, and 496 who remained T2DM and CAD free during a mean follow-up of 6.1

2018 Journal of Clinical Endocrinology and Metabolism

13. Allopurinol in Diabetes Mellitus and Multivessel Coronary Artery Disease

markers of inflammation and improve quality of life and major adverse cardiovascular effects (MACE). Condition or disease Intervention/treatment Phase Diabetes Mellitus Ischemic Heart Disease Multi Vessel Coronary Artery Disease Drug: Allopurinol Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 100 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose (...) information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: No Keywords provided by michal roll, Tel-Aviv Sourasky Medical Center: Diabetes Mellitus Uric asid Multi Vessel Coronary Artery Disease Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases Glucose Metabolism Disorders Metabolic Diseases Endocrine

2018 Clinical Trials

14. Coronary Artery Disease Prevention in Diabetes

Administration 4 Coronary Artery Disease Prevention in Diabetes Coronary Artery Disease Prevention in Diabetes Aka: Coronary Artery Disease Prevention in Diabetes , Cardiac Complication Risk Reduction in Diabetes Mellitus , Cardiovascular Event Prevention in Diabetes Mellitus , Prevention of Diabetes Mellitus Cardiovascular Complications , Diabetes Cardiac Complication Prevention II. Epidemiology Most patients with diabetes die of cardiovascular disease complications (causes 65% of deaths) Glycemic control (...) from a Bing search on the term "Coronary Artery Disease Prevention in Diabetes." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Ontology: Coronary heart disease risk clinical management plan (C1445948) Concepts Intellectual Product ( T170 ) SnomedCT 412781005 English Coronary heart disease risk clinical management plan (qualifier value) , Coronary heart disease risk clinical management plan Spanish plan de manejo clínico

2018 FP Notebook

15. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association

generally outweighs the risks resulting from elevated absolute risks for ASCVD: ≥21 years of age with clinical ASCVD (known coronary artery disease or stroke) and/or significantly elevated LDL-C (≥190 mg/dl) and 40 to 75 years old with diabetes mellitus and/or ≥7.5% 10-year ASCVD risk according to the ACC/AHA ASCVD Risk Calculator. The European Society of Cardiology applied a similar central principle in its 2016 guideline on CVD prevention, although with a different risk prediction model. Although (...) and hypertension should be managed as recommended for the general population because there are insufficient data to recommend a divergent approach in HIV. A practical expert consensus approach to ASCVD risk assessment and primary prevention in HIV that is based on available (albeit incomplete) evidence is provided in . Acute Coronary Syndromes and Secondary Prevention of Coronary Artery Disease PLWH who experience an acute coronary syndrome such as ST-segment–elevation and non–ST-segment–elevation MI tend

2019 American Heart Association

16. Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes

and older; previous myocardial infarction; previous coronary artery bypass grafting (CABG); coronary artery disease with stenosis of 50% or more in at least two vessels; previous ischaemic stroke; previous transient ischaemic attack; carotid stenosis of at least 50%; cerebral revascularisation; diabetes mellitus; peripheral arterial disease; or chronic renal dysfunction, defined as a creatinine clearance of less than 60 ml per minute per 1.73m 2 of body surface area. Ticagrelor should be used (...) Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes '); } else { document.write(' '); } ACE | Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes Search > > Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes - Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes First published on 5 February 2018 Guidance Recommendations The Ministry of Health's Drug Advisory Committee

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

17. Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial. (Abstract)

Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial. Lower extremity arterial disease (LEAD) occurs more common in patients with diabetes than without diabetes. Microvascular complications of diabetes contribute to higher rates of adverse limb events in patients with LEAD. Blood flow in the macrocirculation and microcirculation is reduced with increasing low-shear and high-shear (...) blood viscosity. We hypothesize that the adenosine enhancing properties of ticagrelor will reduce low-shear blood viscosity and improve microcirculatory flow in the dorsum of the feet of patients with type 2 diabetes. Ticagrelor is a P2Y12 receptor antagonist with evidence of cardiovascular event reduction in patients with acute coronary syndromes and those with a previous myocardial infarction. In a large multicenter trial of patients with symptomatic LEAD and a history of limb revascularization

2018 Cardiovascular Drugs and Therapy

18. Androgens, irregular menses, and risk of diabetes and coronary artery calcification in the Diabetes Prevention Program. Full Text available with Trip Pro

Androgens, irregular menses, and risk of diabetes and coronary artery calcification in the Diabetes Prevention Program. It is unclear whether relative elevations in androgens or irregular menses (IM) are associated with greater cardiometabolic risk among women who are already overweight and glucose intolerant.We conducted a secondary analysis of the Diabetes Prevention Program (DPP) and the Diabetes Prevention Program Outcomes Study (DPPOS). Participants included women with sex hormone (...) measurements who did not use exogenous estrogen (n = 1422). We examined whether free androgen index (FAI) or IM was associated with diabetes risk during the DPP/DPPOS or with coronary artery calcification (CAC) at DPPOS year 10. Models were adjusted for menopausal status, age, race or ethnicity, randomization arm, body mass index (BMI), and hemoglobin A1c.Women had an average age of 48.2 ± 9.9 years. Elevations in FAI and IM were associated with greater BMI, waist circumference, and blood pressure

2017 Journal of Clinical Endocrinology and Metabolism Controlled trial quality: uncertain

19. Stable Coronary Artery Disease (2nd Edition)

Management 91 11. FOLLOW-UP OF PATIENTS WITH STABLE CAD 93 12. PRE-OPERATIVE ASSESSMENT FOR ELECTIVE NON-CARDIAC SURGERY 95 13. MONITORING AND QUALITY ASSURANCE 97 REFERENCES 98 ACKNOWLEDGMENTS 123 DISCLOSURE STATEMENT 123 SOURCES OF FUNDING 123 6 Rationale: Coronary Artery Disease (CAD) covers a wide spectrum from asymptomatic individuals to patients with stable CAD, Acute Coronary Syndromes (ACS) and Sudden Cardiac Death (SCD). This Clinical Practice Guidelines (CPG) on Stable CAD is directed (...) Modification Therapy BP Blood Pressure CABG Coronary Artery Bypass Surgery CAD Coronary Artery Disease CAC Coronary Calcium Score CASS Coronary Artery Surgery Study CCB Calcium Channel Blockers CCS Canadian Cardiovascular Society CHF Congestive Heart Failure CHO Carbohydrate CKD Chronic Kidney Disease CMR Cardiac Magnetic Resonance CPG Clinical Practice Guidelines CT Computerised Tomographic CTA Computerised Tomographic Angiography CV Cardiovascular CVD Cardiovascular Disease DAPT Dual Antiplatelet Therapy

2018 Ministry of Health, Malaysia

20. Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD Full Text available with Trip Pro

for the management of patients with diabetes and acute or chronic coronary syndromes 33 Recommendations for coronary revascularization in patients with diabetes 35 Recommendations for the type of revascularization in patients with diabetes with stable coronary artery disease, suitable coronary anatomy for both procedures, and low predicted surgical mortality 36 Recommendations for the treatment of heart failure in patients with diabetes 39 Recommendations for the treatment of patients with type 2 diabetes (...) Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus CAROLINA Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes CCS Chronic coronary syndrome CE Cardiac event CHA 2 DS 2 -VASc Congestive heart failure, Hypertension, Age ≥75 years (Doubled), Diabetes mellitus, Stroke or transient ischaemic attack (Doubled), Vascular disease, Age 65–74 years, Sex category CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic

2019 European Society of Cardiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>